VRC-HIVMAB075-00-AB

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV PreventionHIV-1

Phase 1

Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

CompletedNCT02840474

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1

Start: 2017-04-24End: 2020-01-15Updated: 2025-01-30

VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

CompletedNCT03015181

National Institute of Allergy and Infectious Diseases (NIAID)HIV Prevention

Start: 2017-02-21End: 2018-07-10Updated: 2020-10-26

Related Papers

Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection

JCI Insight2025-02-235 citations

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.

2019-08-2892 citations

Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial

BMJ Open2019-07-0116 citations